Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System

While assessing the efficacy of erlotinib in patients with epidermal growth factor receptor (EGFR) wild-type (WT) non-small-cell lung cancer (NSCLC), the sensitivity of the method used for the EGFR mutation analysis may affect the evaluation of the efficacy. We conducted a phase II study of erlotini...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: MORISE, MASAHIRO, TANIGUCHI, HIROYUKI, SAKA, HIDEO, SHINDOH, JOE, SUZUKI, RYUJIRO, KOJIMA, EIJI, HASE, TETSUNARI, ANDO, MASAHIKO, KONDO, MASASHI, SAITO, HIROSHI, HASEGAWA, YOSHINORI
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: D.A. Spandidos 2014
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4179810/
https://ncbi.nlm.nih.gov/pubmed/25279187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2014.354
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller